Tatsuya Yoshida

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.1K citations

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pharmacology +6

Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments

Shogo Kumagai, Shohei Koyama, Kota Itahashi et al. · Cancer Cell · 2022 · 752 citations

Cancer Immunosurveillance, Pd-1 Expression, Medicine +11

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Jonathan W. Goldman, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet Oncology · 2020 · 662 citations · Full text

Platinum–etoposide Versus Platinum–etoposide, Medicine, Pathology +6

Narrow-band imaging system with magnifying endoscopy for superficial esophageal lesions

Tatsuya Yoshida, Haruhiro Inoue, Shinsuke Usui et al. · Gastrointestinal Endoscopy · 2004 · 424 citations

Endoscopy, Esophagus, Esophageal Cancer +9

Differential Crizotinib Response Duration Among <i>ALK</i> Fusion Variants in <i>ALK</i>-Positive Non–Small-Cell Lung Cancer

Tatsuya Yoshida, Yuko Oya, Kosuke Tanaka et al. · Journal of Clinical Oncology · 2016 · 250 citations